Purple biotech advances nt219 into phase 2 head and neck cancer trial

Nt219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (keytruda) or cetuximab (erbitux)

PPBT Ratings Summary

PPBT Quant Ranking